Impact Events
MoreDate | Lead Company | Event | Type | Approval Change | Approval Likelihood |
---|---|---|---|---|---|
4/21/25 | Gilead (GILD) | Trodelvy for Triple-Negative Breast Cancer (TNBC) | Subscribers Only | Subscribers Only | Subscribers Only |
4/17/25 | Eli Lilly (LLY) | Orforglipron for Diabetes Mellitus, Type II | Subscribers Only | Subscribers Only | Subscribers Only |
4/14/25 | Bristol (BMY) | Camzyos for Cardiomyopathy - Hypertrophic | Subscribers Only | Subscribers Only | Subscribers Only |
4/1/25 | Alzheon | ALZ-801 for Alzheimer's Disease (AD) | Subscribers Only | Subscribers Only | Subscribers Only |
4/1/25 | Cerevance | CVN424 for Parkinson's Disease (PD) | Subscribers Only | Subscribers Only | Subscribers Only |
Upcoming Catalysts
MoreExpected Date Range | Lead Company | Drug | Expected Catalyst |
---|---|---|---|
03/31/2025 | Subscribers Only | Subscribers Only | Trial Announcement - Other |
04/01/2025 | Subscribers Only | Subscribers Only | Company - Divestment/Spinoff |
04/05/2025 | Subscribers Only | Subscribers Only | Trial Data - Other |
04/24/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
04/24/2025 | Subscribers Only | Subscribers Only | Trial Data - Updated Results |